Reported about 1 month ago
In a recent segment, Mizuho Americas analyst Salim Syed endorsed Enliven Therapeutics (ELVN) as his top biotech pick, citing promising developments in their drug ELVN-001 for chronic myeloid leukemia. With the global market for CML growing rapidly, he believes the drug could generate significant revenue. Conversely, he expressed concerns about Amgen (AMGN), highlighting difficulties in its valuation and upcoming data releases that could lead to drastic stock price fluctuations.
Source: YAHOO